We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

43 hedge funds and large institutions have $113M invested in Monopar Therapeutics in 2025 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 15 increasing their positions, 4 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

275% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 4

73% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 11

23% more funds holding

Funds holding: 35 → 43 (+8)

4.63% more ownership

Funds ownership: 47.31% → 51.94% (+4.6%)

4% more capital invested

Capital invested by funds: $109M → $113M (+$3.93M)

Holders
43
Holders Change
+8
Holders Change %
+22.86%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
15
Reduced
4
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.93M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.76M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$1.38M
4
ABG
Ally Bridge Group
New York
+$1.25M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.14M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.33M
2
Millennium Management
Millennium Management
New York
-$1.66M
3
Marshall Wace
Marshall Wace
United Kingdom
-$946K
4
Goldman Sachs
Goldman Sachs
New York
-$673K
5
Jane Street
Jane Street
New York
-$377K
Name Holding Trade Value Shares
Change 		Change in
Stake
PAS
51
Point72 Asia (Singapore)
Singapore
– -$64.1K -1,761 Closed
TRCT
52
Tower Research Capital (TRC)
New York
– -$11K -303 Closed
PD
53
Point72 (DIFC)
United Arab Emirates
– -$7.13K -196 Closed
FDCDDQ
54
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$583 -16 Closed
1 2
3

MNPR Hedge Fund Activity: Q2 2025 in Review

43 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q2 2025, worth a combined $113M — up 3.6% from $109M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new MNPR positions and 11 closed out — a net gain of 8 holders — while 15 added to existing stakes and 4 trimmed.

The largest buyer was BlackRock, adding an estimated $6.93M. The largest seller was Point72 Asset Management, cutting an estimated $2.33M.

  • 43 institutional investors held Monopar Therapeutics (MNPR) as of Q2 2025, up from 35 in Q1 2025.
  • Funds reported $113M of Monopar Therapeutics stock for Q2 2025, up 3.6% quarter-over-quarter.
  • 19 funds opened new Monopar Therapeutics positions in Q2 2025 and 11 closed out, a net change of +8 holders.
  • The largest Monopar Therapeutics buyer in Q2 2025 was BlackRock, an estimated $6.93M added.
  • The largest Monopar Therapeutics seller in Q2 2025 was Point72 Asset Management, an estimated $2.33M sold.

Based on aggregated 13F filings for Q2 2025.